Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859521 · ClinicalTrials.gov registry record · Phase 1
Levetiracetam 1000 mg Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00859521: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00859521 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00859521, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
THe objective of this study is to compare the rate and extent of absorption of an investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the commercially available reference product under fasting conditions.
Interventions
- DRUG Levetiracetam
- DRUG Keppra®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859521
The ClinicalTrials.gov registry entry for NCT00859521 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levetiracetam is the first listed.
NCT00859521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00859521 about?
NCT00859521 is a clinical study titled "Levetiracetam 1000 mg Under Fasting Conditions". THe objective of this study is to compare the rate and extent of absorption of an investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the commercially available reference product under fasting conditions.
What is the current status of trial NCT00859521?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-01. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00859521?
The interventions under investigation include: Levetiracetam (DRUG), Keppra® (DRUG).
Who is sponsoring clinical trial NCT00859521?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.